Literature DB >> 32845775

Glycoprotein VI Blockade: Not Just Targeting Collagen Anymore?

Shuchi Gupta1, Lawrence F Brass1.   

Abstract

Entities:  

Keywords:  Editorials; collagen; glycoprotein VI; platelet activation; stroke; von Willebrand factor

Mesh：

Substances：

Year:  2020        PMID： 32845775      PMCID： PMC7462092          DOI： 10.1161/ATVBAHA.120.315059

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN： 1079-5642            Impact factor:   8.311


× No keyword cloud information.
  20 in total

1.  Genetic and antibody-induced glycoprotein VI deficiency equally protects mice from mechanically and FeCl(3) -induced thrombosis.

Authors:  M Bender; I Hagedorn; B Nieswandt
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

2.  A humanized glycoprotein VI (GPVI) mouse model to assess the antithrombotic efficacies of anti-GPVI agents.

Authors:  Pierre Henri Mangin; ChaoJun Tang; Catherine Bourdon; Stéphane Loyau; Monique Freund; Béatrice Hechler; Christian Gachet; Martine Jandrot-Perrus
Journal:  J Pharmacol Exp Ther       Date:  2012-01-11       Impact factor: 4.030

3.  Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans.

Authors:  Martin Ungerer; Kai Rosport; Andreas Bültmann; Richard Piechatzek; Kerstin Uhland; Peter Schlieper; Meinrad Gawaz; Götz Münch
Journal:  Circulation       Date:  2011-04-18       Impact factor: 29.690

4.  The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion.

Authors:  Kazunobu Kato; Taisuke Kanaji; Susan Russell; Thomas J Kunicki; Kenichi Furihata; Sachiko Kanaji; Patrizia Marchese; Armin Reininger; Zaverio M Ruggeri; Jerry Ware
Journal:  Blood       Date:  2003-05-08       Impact factor: 22.113

Review 5.  Functional significance of the platelet immune receptors GPVI and CLEC-2.

Authors:  Julie Rayes; Steve P Watson; Bernhard Nieswandt
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

6.  A compound heterozygous mutation in glycoprotein VI in a patient with a bleeding disorder.

Authors:  C Hermans; C Wittevrongel; C Thys; P A Smethurst; C Van Geet; K Freson
Journal:  J Thromb Haemost       Date:  2009-06-22       Impact factor: 5.824

7.  Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice.

Authors:  B Nieswandt; V Schulte; W Bergmeier; R Mokhtari-Nejad; K Rackebrandt; J P Cazenave; P Ohlmann; C Gachet; H Zirngibl
Journal:  J Exp Med       Date:  2001-02-19       Impact factor: 14.307

8.  Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks.

Authors:  Kristell Lebozec; Martine Jandrot-Perrus; Gilles Avenard; Olivier Favre-Bulle; Philippe Billiald
Journal:  MAbs       Date:  2017-06-09       Impact factor: 5.857

9.  Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation.

Authors:  Lionel Renaud; Kristell Lebozec; Christine Voors-Pette; Peter Dogterom; Philippe Billiald; Martine Jandrot Perrus; Yannick Pletan; Matthias Machacek
Journal:  J Clin Pharmacol       Date:  2020-06-04       Impact factor: 3.126

10.  Immobilized fibrinogen activates human platelets through glycoprotein VI.

Authors:  Pierre H Mangin; Marie-Blanche Onselaer; Nicolas Receveur; Nicolas Le Lay; Alexander T Hardy; Clare Wilson; Ximena Sanchez; Stéphane Loyau; Arnaud Dupuis; Amir K Babar; Jeanette Lc Miller; Helen Philippou; Craig E Hughes; Andrew B Herr; Robert As Ariëns; Diego Mezzano; Martine Jandrot-Perrus; Christian Gachet; Steve P Watson
Journal:  Haematologica       Date:  2018-02-22       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.